Polls are closed and the election results are in regarding the proposals to tax sugary beverages in Berkeley and San Francisco. The verdict? Well, you win some, you lose some.
WScreen Shot 2014-01-23 at 1.20.11 PMhile we don t always agree with the FDA s actions, yesterday the agency resoundingly rejected two citizens petitions that asked the FDA to ban the use of aspartame as a food additive. Kudos to the FDA!
It is a very sad day at ACSH. Our good friend Jimmy Capuano passed away yesterday after a seven-year battle with colon cancer. His battle was nothing short of extraordinary.
Bariatric surgery is perhaps the most effective means of combatting obesity, and according to the Journal of the American College of Surgery, some form of that surgery was chosen by over 120,000 people in 2008. There is, however, more than one type of bariatric surgery, and until recently it wasn t clear which would be better in terms of post-operative complications, the rate of re-hospitalization, or the efficacy of different procedures.
on Entine, the executive director of the Genetic Literacy Project, and a Senior Fellow at the World Food Center, Institute for Food and Agricultural Literacy at the University of California-Davis (and author of ACSH s Chemophobia
According to the CDC, one in 68 children in the United States has an autism spectrum disorder (ASD). In Denmark, that number is one in 100. The prevalence of ASD has increased significantly over the last thirty years. In order to explain this increase, everything from vaccines to pesticides to mercury have been blamed
Today s NYTimes Personal Health column by Jane E. Brody could pass for an ACSH publication: Emotion Is Not the Best Medicine. How many times have we said that? She uses the Ebola hysteria as her hook, but the column is replete with wise words.
The latest health news: The relaxed approach on concussions, another study points to e-cig safety, and why the Food Babe is wrong on toxins in chocolate.. and everything else.
n 1976, Tagamet (cimetidine) was approved in Britain, and three years later the FDA followed suit. It was the first drug designed to treat heartburn and ulcers by reducing the production of stomach acid, rather than simply trying to neutralize it with antacids. It worked very well. Its inventors, Smith, Kline and French (now part of Glaxo) were rewarded for their effort; Tagamet became the first $1 billion selling drug ever.
More science on the toxins in e-cigarettes and their vapors shows, again, nothing to worry about. Will this finally silence (or at least quiet) their science-free opponents? Not very likely.
